FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
- Cramer Goes One-on-One With Costco CEO
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Beware of bylines, Cramer said during Tuesday’s Mad Money. A series of negative news stories can do more damage to a stock than a bad earnings report.
More specifically, this has to do with what Cramer sees as a media-wide loathing of Big Pharma, much in the same way the Democrats dislike the group. Once a reporter’s mind is made up, not even the best stocks can withstand the attacks, “even if,” he said, “there’s no news in the articles.” Cramer’s charitable trust sold off its Schering-Plough [SGP
Loading...
()
] shares for this very reason.
Who was the culprit? The New York Times’ Alex Berenson.
Schering-Plough has taken a lot of hits for its shared cholesterol franchise, shared with Merck [MRK
Loading...
()
], consisting of Vytorin and Zetia, and Berenson has been getting his whacks in every step of the way. In the past 18 months, he’s written 10 articles about the two treatments on everything from unpublished side effects to delayed trial results to the high cost for patients.
Read Berenson’s latest, “For Widely Used Drug, Question of Usefulness Is Still Lingering,” another negative article about the two drugs.
Now Cramer’s not slagging Berenson or saying that his work is off point at all. In fact, Berenson worked at TheStreet.com immediately after he finished school. This guy’s a pro, and his stories are spot on. But Berenson’s relentless press about Schering and Vytorin make the stock too difficult to own.
Note: Don’t confuse Berenson’s consistency with a one-off article that hurts a company for a day. That’s what happened to Genentech [DNA
Loading...
()
] when the Times criticized the high costs of that company’s cancer drug Avastin. The stock’s rebounded 29% since that July 6 story.
The lesson here is that often times bylines are the same as “sell lines.” And right now that’s the case, no matter how good a company is may be, for Schering-Plough.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes